Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the efficacy of irbesartan on the progression of
liver fibrosis in adult patients with chronic hepatitis C.
The expected total enrollment is 200 patients. Patients who meet the study criteria and
accept to participate at this study will take by day one tablet of 150 mg of treatment
(irbesartan or placebo) during two years. The assessment of efficacy will be make by
evaluation of area of liver fibrosis and blood markers of liver fibrosis
Phase:
Phase 3
Details
Lead Sponsor:
ANRS, Emerging Infectious Diseases French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)